Ingredient or product comparison
GHK-Cu for Keloid Scars Research: Comparison of Treatment Modalities
Before examining how GHK-Cu fits into keloid research frameworks, it's useful to understand where peptide-based modulation sits relative to established interventions. GHK-Cu (research peptide) TGF-β1 suppression, MMP-2 upregulation 40–60% reduction in pro-fibr
This source-based comparison does not add ratings or recommend a winner.
- Before examining how GHK-Cu fits into keloid research frameworks, it's useful to understand where peptide-based modulation sits relative to established interventions.
- GHK-Cu (research peptide)
- TGF-β1 suppression, MMP-2 upregulation
- 40–60% reduction in pro-fibrotic signaling in vitro; no completed human trials
- In vitro only; delivery challenges; copper stability issues
- Promising for understanding keloid biology; not validated for clinical treatment
- Intralesional corticosteroids (triamcinolone)
- Suppresses fibroblast proliferation, reduces inflammation
- 50–100% keloid volume reduction in 60–70% of patients (clinical data)
- Requires repeated injections; skin atrophy; hypopigmentation
- Clinical standard of care; proven but invasive
- 5-Fluorouracil (5-FU)
- Inhibits fibroblast DNA synthesis
- 45–75% response rate when combined with steroids
- Local ulceration; pain at injection site
- Effective adjunct therapy; better when combined
- Silicone gel sheeting
- Hydration-mediated reduction in collagen production
- Modest improvement (10–30% flattening) over 3–6 months
- Requires 12+ hours daily use; compliance issues
- Non-invasive; limited efficacy as monotherapy
- Surgical excision
- Physical removal of keloid tissue
- 45–100% recurrence rate when used alone
- High recurrence without adjunct therapy
- Rarely used as standalone; combined with radiation or steroids